Canada · Delayed Price · Currency is CAD Profound Medical Earnings Call Transcripts
Fiscal Year 2026
-
TULSA, an AI-driven, MRI-guided, incision-free prostate therapy, is gaining traction with strong clinical data, expanding insurance coverage, and a growing addressable market in prostate cancer and BPH. High margins and partnerships with major MRI companies support robust financial growth.
-
Six-month CAPTAIN trial data show TULSA outperforms surgery in safety and functional recovery for intermediate-risk prostate cancer, with rapid patient recovery and strong quality-of-life outcomes. TULSA's inclusion in the 2025 NCCN guidelines and robust evidence base position it for broader adoption and payer coverage as further oncologic data matures.
Fiscal Year 2025
-
Q4 2025 revenue rose 43% year-over-year to $6M, with gross margin at 67% and a net loss of CAD 8.2M. The company expects high double-digit to low triple-digit revenue growth in 2026, driven by TULSA-PRO adoption, new clinical evidence, and favorable reimbursement trends.
-
Q3 2025 revenue surged 87% year-over-year to $5.3M, with gross margin rising to 74.3% and net loss narrowing. Commercial momentum is strong, with 70 TULSA-PRO sites and a robust pipeline, while management maintains a 70% annual growth target.
-
TULSA-PRO is driving rapid adoption and revenue growth, with expanding reimbursement, major hospital partnerships, and strong clinical data supporting its MR-guided, AI-driven prostate and BPH treatments. The company targets 200 sites and is launching new software and products for broader market reach.
-
Q2 2025 revenue was flat year-over-year at $2.2M, but gross margin rose to 73%. Net loss widened to $15.7M as operating expenses increased. Management maintains 70%-75% full-year revenue growth guidance, citing a strong sales pipeline and new product launches.
-
Q1 2025 revenue grew 82% year-over-year to $2.6M, with gross margin rising to 71%. Strong CAPTAIN trial data and new AI modules are driving adoption, while management maintains 70%-75% annual growth guidance and expects a back-end loaded year.
-
TULSA's CAPTAIN trial confirms superior perioperative outcomes and patient experience over robotic prostatectomy, with rapid adoption driven by new AI modules, expanded BPH indication, and favorable reimbursement. Market interest and physician training are accelerating, positioning TULSA for strong growth.
-
The conference highlighted rapid adoption and strong clinical outcomes for an AI-enhanced, MRI-guided prostate treatment, now supported by superior CMS reimbursement and expanding into BPH and women's health. Strategic partnerships and a robust pipeline position the company for high double-digit growth.
Fiscal Year 2024
-
Q4 2024 saw record revenue and gross margin, with a significant reduction in net loss and a strong cash position. The company expects high double-digit growth in 2025 and triple-digit growth in 2026, driven by new product launches, expanded reimbursement, and a strengthened commercial team.
-
TULSA-PRO's CMS Level 7 reimbursement removes a major adoption barrier, enabling broad use in hospitals, ASCs, and offices. AI-driven, MRI-guided ablation offers high precision, minimal side effects, and strong clinical evidence, with a large addressable market and new commercial leadership driving growth.
-
Q3 2024 revenue grew 64% year-over-year to $2.83M, with improved gross margin and strong recurring revenue. CMS finalized higher reimbursement for TULSA, supporting a shift to a traditional device model and expected growth in installations and utilization.
-
Q2 2024 revenue grew 39% year-over-year to $2.23 million, with improved net loss and strong cash reserves. New reimbursement codes and AI modules are driving adoption, and the company reaffirms its 2024 guidance and install base targets.